stab at a china financial model, page-3

Addendum to previous post (needed to include the
per annum tag for relevant lines of the model)


The Finacial Model (after Year 2)

Target Population 750,000,000

Target rate @ 10% 75,000,000
Per annum

Margin on each test A$0.75

SBN revenue (membrane only) A56,250,000
Per annum

50% model discount A28,125,000
applied Per annum

SBN EBITDA A28,125,000
Per annum

Business multiple X20
(conservative for Biotech Cos) X10

Market Capitalisation A281,250,000

Number of shares (undiluted) 750,000,000

SP A$0.375



This model has a 50% dicount applied and ignores any potential revenue generated from the 15% equity which would include full retail price margins on the total product including the membrane.